NOVAVAX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.04 USD | -1.38% |
|
-2.97% | +213.33% |
| Sales 2024 * | 987M 81.88B | Sales 2025 * | 552M 45.83B | Capitalization | 2.11B 175B |
|---|---|---|---|---|---|
| Net income 2024 * | 68M 5.64B | Net income 2025 * | -98M -8.13B | EV / Sales 2024 * | 1.29 x |
| Net cash position 2024 * | 837M 69.49B | Net cash position 2025 * | 704M 58.45B | EV / Sales 2025 * | 2.55 x |
| P/E ratio 2024 * |
35.6
x | P/E ratio 2025 * |
-35.4
x | Employees | 1,543 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.14% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novavax, Inc.
More recommendations
More press releases
More news
| 1 day | -1.38% | ||
| 1 week | -2.97% | ||
| Current month | +0.07% | ||
| 1 month | +219.32% | ||
| 3 months | +179.04% | ||
| 6 months | +170.02% | ||
| Current year | +213.33% |
1 week
13.50
15.70
1 month
4.4317.40
Current year
3.5317.40
1 year
3.5317.40
3 years
3.53277.80
5 years
3.53331.68
10 years
3.53331.68
| Managers | Title | Age | Since |
|---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 57 | 23/23/23 |
John Trizzino
PSD | President | 64 | 10/14/10 |
James Kelly
DFI | Director of Finance/CFO | 58 | 16/21/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 29/22/29 |
Gregg Alton
BRD | Director/Board Member | 58 | 01/20/01 |
David Mott
BRD | Director/Board Member | 58 | 16/20/16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.31% | 17 M€ | +7.28% | - | |
| 0.15% | 0 M€ | 0.00% | - | |
| 0.13% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 15.03 | -1.44% | 15,742,321 |
| 30/24/30 | 15.25 | +0.93% | 10,145,110 |
| 29/24/29 | 15.11 | -2.61% | 9,993,751 |
| 28/24/28 | 15.52 | +0.10% | 19,115,523 |
Delayed Quote Nasdaq, May 01, 2024 at 01:30 am IST
More quotes
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Companyâs proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Calendar
07/06/2024
- Jefferies Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
15.03
USD
Average target price
21.6
USD
Spread / Average Target
+43.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +213.33% | 2.11B | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B | |
| -11.83% | 10.74B |
- Stock Market
- Equities
- NVAX Stock
